Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Garsorasib |
| Synonyms | |
| Therapy Description |
Garsorasib (D-1553) inhibits KRAS G12C, which potentially results in decreased tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 932, PMID: 36948246). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Garsorasib | D1553|D 1553|D-1553 | KRAS G12C inhibitor 36 | Garsorasib (D-1553) inhibits KRAS G12C, which potentially results in decreased tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 932, PMID: 36948246). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04585035 | Phase Ib/II | Garsorasib | Study to Evaluate D-1553 in Subjects With Solid Tumors | Active, not recruiting | USA | AUS | 2 |